BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17982669)

  • 1. Knock-down of calcitonin receptor expression induces apoptosis and growth arrest of prostate cancer cells.
    Thomas S; Muralidharan A; Shah GV
    Int J Oncol; 2007 Dec; 31(6):1425-37. PubMed ID: 17982669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcitonin receptor-stimulated migration of prostate cancer cells is mediated by urokinase receptor-integrin signaling.
    Thomas S; Chiriva-Internati M; Shah GV
    Clin Exp Metastasis; 2007; 24(5):363-77. PubMed ID: 17487556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitonin increases tumorigenicity of prostate cancer cells: evidence for the role of protein kinase A and urokinase-type plasminogen receptor.
    Thomas S; Chigurupati S; Anbalagan M; Shah G
    Mol Endocrinol; 2006 Aug; 20(8):1894-911. PubMed ID: 16574742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitonin promotes in vivo metastasis of prostate cancer cells by altering cell signaling, adhesion, and inflammatory pathways.
    Shah GV; Thomas S; Muralidharan A; Liu Y; Hermonat PL; Williams J; Chaudhary J
    Endocr Relat Cancer; 2008 Dec; 15(4):953-64. PubMed ID: 18784182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A-kinase anchoring protein 2 is required for calcitonin-mediated invasion of cancer cells.
    Thakkar A; Aljameeli A; Thomas S; Shah GV
    Endocr Relat Cancer; 2016 Jan; 23(1):1-14. PubMed ID: 26432469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcitonin induces apoptosis resistance in prostate cancer cell lines against cytotoxic drugs via the Akt/survivin pathway.
    Thomas S; Shah G
    Cancer Biol Ther; 2005 Nov; 4(11):1226-33. PubMed ID: 16222118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcitonin induces stem cell-like phenotype in prostate cancer cells.
    Aldahish A; Kale A; Aljameeli A; Shah GV
    Endocr Relat Cancer; 2019 Nov; 26(11):815-828. PubMed ID: 31561211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action.
    Sabbisetti VS; Chirugupati S; Thomas S; Vaidya KS; Reardon D; Chiriva-Internati M; Iczkowski KA; Shah GV
    Int J Cancer; 2005 Nov; 117(4):551-60. PubMed ID: 15929083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcitonin receptor increases invasion of prostate cancer cells by recruiting zonula occludens-1 and promoting PKA-mediated TJ disassembly.
    Aljameeli A; Thakkar A; Shah G
    Cell Signal; 2017 Aug; 36():1-13. PubMed ID: 28428082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
    Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
    J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcitonin stimulates the secretion of urokinase-type plasminogen activator from prostate cancer cells: its possible implications on tumor cell invasion.
    Sabbisetti V; Chigurupati S; Thomas S; Shah G
    Int J Cancer; 2006 Jun; 118(11):2694-702. PubMed ID: 16381004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiling of the calcitonin-calcitonin receptor axis in primary prostate cancer: clinical implications and molecular correlates.
    Thakkar A; Bijnsdorp IV; Geldof AA; Shah GV
    Oncol Rep; 2013 Sep; 30(3):1265-74. PubMed ID: 23820954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcitonin Receptor-Zonula Occludens-1 Interaction Is Critical for Calcitonin-Stimulated Prostate Cancer Metastasis.
    Aljameeli A; Thakkar A; Thomas S; Lakshmikanthan V; Iczkowski KA; Shah GV
    PLoS One; 2016; 11(3):e0150090. PubMed ID: 26934365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth.
    Bindukumar B; Schwartz SA; Nair MP; Aalinkeel R; Kawinski E; Chadha KC
    Neoplasia; 2005 Mar; 7(3):241-52. PubMed ID: 15799824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitonin is a prostate epithelium-derived growth stimulatory peptide.
    Chien J; Ren Y; Qing Wang Y; Bordelon W; Thompson E; Davis R; Rayford W; Shah G
    Mol Cell Endocrinol; 2001 Jul; 181(1-2):69-79. PubMed ID: 11476942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
    Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
    Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cadherin switching and activation of beta-catenin signaling underlie proinvasive actions of calcitonin-calcitonin receptor axis in prostate cancer.
    Shah GV; Muralidharan A; Gokulgandhi M; Soan K; Thomas S
    J Biol Chem; 2009 Jan; 284(2):1018-30. PubMed ID: 19001380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
    Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
    Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a small molecule class to enhance cell-cell adhesion and attenuate prostate tumor growth and metastasis.
    Shah GV; Muralidharan A; Thomas S; Gokulgandhi M; Mudit M; Khanfar M; El Sayed K
    Mol Cancer Ther; 2009 Mar; 8(3):509-20. PubMed ID: 19276166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.